In vivo imaging of mGlu5 receptor expression in humans with Fragile X Syndrome towards development of a potential biomarker

Maria Mody1,5*, Yoann Petibon2,5, Paul Han2, Darshini Kuruppu3, Chao Ma2, Daniel Yokell2, Ramesh Neelamegam4, Marc D. Normandin2, Georges El Fakhri2 & Anna-Liisa Brownell2

Fragile X Syndrome (FXS) is a neurodevelopmental disorder caused by silencing of the Fragile X Mental Retardation (FMR1) gene. The resulting loss of Fragile X Mental Retardation Protein (FMRP) leads to excessive glutamate signaling via metabotropic glutamate subtype 5 receptors (mGluR5) which has been implicated in the pathogenesis of the disorder. In the present study we used the radioligand 3-[18F]fluoro-5-(2-pyridinylethynyl)benzonitrile ([18F]FPEB) in simultaneous PET-MR imaging of males with FXS and age- and gender-matched controls to assess the availability of mGlu5 receptors in relevant brain areas. Patients with FXS showed lower [18F]FPEB binding potential (p < 0.01), reflecting reduced mGluR5 availability, than the healthy controls throughout the brain, with significant group differences in insula, anterior cingulate, parahippocampal, inferior temporal and olfactory cortices, regions associated with deficits in inhibition, memory, and visuospatial processes characteristic of the disorder. The results are among the first to provide in vivo evidence of decreased availability of mGluR5 in the brain in individuals with FXS than in healthy controls. The consistent results across the subjects, despite the tremendous challenges with neuroimaging this population, highlight the robustness of the protocol and support for its use in drug occupancy studies; extending our radiotracer development and application efforts from mice to humans.

Fragile X Syndrome (FXS) is a leading cause of inherited intellectual disability1 and the most common, known single gene cause of autism spectrum disorder2,3. Successful treatment of FXS has the potential to positively impact the larger field of neurodevelopmental disabilities. A number of studies have implicated metabotropic glutamate subtype 5 receptors (mGluR5) in FXS;4 the use of mGluR5 antagonists in Fmr1 Knockout (KO) mouse models has demonstrated a variety of benefits including reduced seizures, anxiety, and behavioral issues5,6. The Fmr1 KO mouse model has shown that the absence of FMRP leads to increased protein synthesis at the synapse and excessive mGluR5 glutamameric signaling7, building on the work of Weiler and colleagues who first identified the connection between FMRP and mGluR5 pathways8. However, despite these promising preclinical findings, clinical trials of mGluR5-targeted drugs in FXS have met with limited success. It is unclear as to whether these trials were conducted with optimal outcome endpoints or in the most appropriate age group9–11.

The severity of FXS phenotype is known to be correlated with the magnitude of the FMRP deficit12. The FMR1 gene responsible for FXS is located on the X chromosome, thereby affecting males with FXS more severely than their female counterpart who have one unaffected X chromosome to fall back on13. We focused on measuring the availability and distribution of mGluR5 in males with FXS and age- and gender-matched healthy controls to better understand the role of mGluR5 expression in the pathophysiology of FXS in humans. Given the heterogeneity found in neurodevelopmental disorders like FXS, stringent methodological standards were used to obtain reliable delineation and quantification of mGluR5 occupancy differences between healthy and disorder groups, critical for biomarker research.

1Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA. 2Gordon Center for Medical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA. 3Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA. 4Department of Radiology, University of Texas Health Science at San Antonio, San Antonio, TX 78229, USA. 5These authors contributed equally: Maria Mody and Yoann Petibon. *email: maria.mody@mgh.harvard.edu
In the present study, we examined PET data from five adult males with FXS (> 200 CGG repeats, full mutation, 26–48 years of age; mean: 34.8 years ± 7.8) and seven age-matched males with normal development (22–43 years of age; mean 31.4 years ± 7.5) from whom PET and MRI data was successfully obtained (see “Methods” for details). Participants with FXS were recruited from the hospital database, local clinics and Fragile X organizations; typical controls (TC) were drawn from the local community. All subjects completed a high resolution MRI and 90-min dynamic PET examination on an integrated whole-body PET-MR (Siemens Biograph mMR) following an intravenous bolus injection of 5 mCi of [18F]FPEB, a safe and reliable radioligand for quantifying regional brain concentrations of mGluR5. Based on Fmr1 mouse studies of the mGluR theory and the established affinity and specificity of [18F]FPEB to mGluR5, we hypothesized that there would be a significant difference in regional brain concentrations of mGluR5 between the two groups of subjects, validating the use of [18F]FPEB in clinical trials as a tool to confirm target engagement of novel drug agents for mGluR5s in FXS and to monitor dose response.

In a recent study, Brašić and colleagues used the same [18F]FPEB tracer in males with FXS, slightly younger than those in the present study, though incorporating different acquisition protocols and data analysis methods for PET across collaborating sites; they found mGluR5 density was significantly reduced in multiple brain regions including the cingulate, cortex, thalamus and striatum, compared to age-matched males with typical development, thereby supporting the use of [18F]FPEB to measure drug occupancy in clinical trials for mGluR5s in FXS.

**Results**

Regional and voxel-wise estimates of [18F]FPEB non-displaceable binding potential (BP_{ND}), a measure of mGluR5 availability, were obtained for each subject by multi-linear reference tissue analysis of dynamic PET data. We found regional brain uptake was consistent with known mGlu5 receptors based on previous studies. A global reduction of [18F]FPEB BP_{ND} was observed in males with FXS compared to control subjects (Fig. 1).

**Figure 1.** Group-average images of [18F]FPEB BP_{ND} in control subjects and subjects with FXS, and corresponding MR template images. Regions exhibiting significant differences in BP_{ND} between control subjects and subjects with FXS (olfactory cortex, parahippocampal gyrus, inferior temporal gyrus, insula, and anterior cingulate gyrus) are indicated in the MR images.

Region of interest analyses confirmed BP_{ND} differences between FXS and control groups (Fig. 2). [18F]FPEB BP_{ND} were significantly lower in subjects with FXS compared to controls in the anterior cingulate gyrus (2.67 ± 0.38 vs. 3.56 ± 0.41; p = 0.004), insula (2.79 ± 0.47 vs. 3.67 ± 0.36; p = 0.009), inferior temporal gyrus (2.41 ± 0.34 vs. 3.19 ± 0.47; p = 0.008), parahippocampal gyrus (2.10 ± 0.32 vs. 2.65 ± 0.32; p = 0.018) and olfactory cortex (2.27 ± 0.30 vs. 2.98 ± 0.34; p = 0.004) (two-tailed unpaired t-tests, corrected for multiple comparisons using FDR (q = 0.05). BP_{ND} was also significantly lower for subjects with FXS subjects in the amygdala (1.70 ± 0.41 vs. 2.25 ± 0.34; p = 0.04), although it did not survive correction for multiple brain region testing. The findings correspond to those in the neuroimaging literature on FXS.
Discussion
Among the core symptoms of FXS is a deficit in visuospatial learning and memory mediated by hippocampus and parahippocampal and inferior temporal regions\(^21,22\). Our findings of significantly lower \(^{[18F]}\)FPEB binding potential (BP\(_{ND}\)) in these areas provide support for the role of mGluR5 in the neurobiology of FXS. Anxiety is frequently reported in this population, which may explain the significant group differences we observed in the insula and olfactory cortex\(^19,23\). Evidence in support of these findings also comes from preclinical studies of the Fmr1 KO mouse using the Morris water maze task and the mirrored chamber test\(^24–26\). Whereas only one of our participants with FXS was on prescription medication for anxiety, a high rate of anxiety in FXS, especially social anxiety, is reported in the literature regardless of gender\(^12,27,28\). The amygdala group differences we observed did not hold up after multiple comparison, but would likely have survived correction in a larger sample. Thus, the finding clearly suggests a need for larger studies, perhaps a narrower age range, and outcome measures to fully capture the profile of the disorder in males and females. Executive functions have also been consistently documented as impaired in FXS\(^29\), implicating the prefrontal cortex. While this area did not show a signal in the present study, it deserves to be examined, especially the gyrus rectus which has been shown to have lower levels of FMRP in individuals with FXS than in controls\(^13\). Taken together, these approaches along with the genetic etiology of FXS will help advance our understanding of gene-brain-behavior relationships in FXS\(^30\) and related neurodevelopmental conditions like autism spectrum disorder\(^31\).

The role of mGluR5 has been extensively studied in mouse models of FXS. However, findings related to mGluR5 expression in animals and autopsies of humans with FXS have been inconsistent. And clinical trials targeting mGluR5 in FXS have met with repeated failure, pointing to a need for better designed studies and reliable biomarkers in individuals with FXS\(^9,32\).

FXS is currently treated symptomatically using behavioral, educational and psychopharmacological strategies\(^33\) often with unsatisfying results\(^34,35\). A targeted treatment is lacking. The results of the present study are important as they pave the way for successful human trials by providing a potential biomarker of the impaired mGluR5 mechanism for use in developing targeted drug therapies in FXS. Specifically, using the radioligand \(^{[18F]}\)FPEB, which has been shown to reliably bind to mGlu5 receptors, we found the binding potential to mGlu5 receptors to be lower throughout the brain in participants with FXS compared with typical controls. The reduced BP appears to reflect reduced density of unoccupied mGlu5 receptors, potentially a downstream consequence of excessive mGlu5 signaling caused by the lack of FMRP protein in individuals with FXS. However, given the lack of consistency of mGlu5 receptor expression findings across human and mouse models, more studies are needed to understand the functional relationship between these variables. Importantly, this difference in BP\(_{ND}\) between the subjects with FXS and control group was significant in areas consistent with known distribution of mGluR5, and which have been functionally implicated in FXS symptomatology. Our results of overall reduced mGlu5 receptor expression in relevant regions of the brain in individuals with FXS replicate recent findings\(^17\) and advance ongoing efforts for a much-needed measure of mGluR5 target engagement for drugs and treatment of symptoms in clinical trials of FXS and related disorders\(^36,37\).

The participants with FXS in the study had the full Fmr1 mutation with CGG repeats greater than 200. However, some individuals with FXS may present with mosaicism (size or methylation mosaics), which can affect FMRP levels and hence the severity of the condition\(^38\). There has been significant progress in understanding the physiological role of mGluR5, but treatment with selective mGluR5 antagonists (e.g., MPEP, CTEP, fenobam) have met with limited success in FXS\(^6,39,40\) despite evidence for use of this approach\(^41\). Factors like age are known to influence treatment efficacy as was seen when MPEP was administered to 2-week- vs. 6-week-old Fmr1 KO

Figure 2. Regional \(^{[18F]}\)FPEB BP\(_{ND}\) in control subjects (blue circle) and subjects with FXS (red square). Error bars indicate standard error of the means. *p<0.05, **p<0.01 (corrected for multiple comparisons).
pants with FXS in the study had an autism diagnosis. However, given the high co-morbidity of FXS and ASD43, study, Brašić and colleagues37, using [18F]FPEB, replicated their earlier findings with FXS; but found that com-

5.15 mCi, SD 0.28; average specific activity at time of injection: 2046 mCi /µmol). Using the published  method48, bolus injection of 5 mCi of 3-[18F]fluoro-5-(2-pyridinylethynyl)benzonitrile ([18F]FPEB) (injected dose: mean

participants were recruited from the local community. They had no history of neurological or psychological prob-

While the caregivers reported a tendency for participants to be anxious in new settings and with strangers, only

Famotidine) for blood pressure and indigestion, and a third on Ritalin (belonging to the stimulant class of drugs)

actual scanner and environment prior to their PET-MR session to help alleviate their anxiety.

provided informed consent and/or assent prior to the experiment and were compensated for their involvement

Taken together with the results from the present study, the field of FXS appears poised for major breakthroughs

treatment using inhibitors targeting increased mGluR5 signaling or cyclic AMP (cAMP) production; offering

In conclusion, the current study supports a role for reduced mGluR5 expression in the underlying patho-

Insofar as the precise modulation of synaptic transmission either through the use of selective mGluR5 inhibi-

Data acquisition. Study subjects were scanned for up to 90-min on an integrated whole-body PET-MR (Siemens Biograph mMR) at the MGH Martins Center for Biomedical Imaging, following an intravenous bolus injection of 5 mCi of 3-[18F]fluoro-5-(2-pyridinylethynyl)benzonitrile ([18F]FPEB) (injected dose: mean 5.15 mCi, SD 0.28; average specific activity at time of injection: 2046 mCi /µmol). Using the published method48, the radioligand was locally synthesized at the Gordon Center for Medical Imaging in Massachusetts General Hospital under the guidelines of the Radioactive Drug Research Committee and the approval from the FDA.

Each dynamic study was divided into three scanning sessions of up to 35-min, with breaks between sessions. A structural MRI scan was acquired for each participant at the beginning of each session using a 3-D T1 weighted multi-echo MPRAGE sequence49 with the following parameters: TR = 2530 ms, TE1 = 1.69, 3.55, 3.41, 7.27 ms,
inversion time = 1100 ms, matrix size = 256 × 256 × 176 and voxel size = 1 × 1 × 1 mm³. An attenuation map for PET was generated based on the structural MRI data using a hybrid segmentation and atlas-based technique

**Data processing and analysis.** Dynamic list-mode PET data for each scanning session were binned into temporal frames of up to 30 s and were reconstructed and corrected for motion using the following multi-step procedure. First, an initial dynamic reconstruction was performed without correction of attenuation, followed by application of spatial Gaussian smoothing (6-mm full width at half maximum—FWHM) to each reconstructed frame and rigid-body alignment of the activity volume for each frame to a selected reference frame. The attenuation map was then registered to the resulting time-averaged volume and transformed using the previously calculated registration parameters, yielding an attenuation map for each frame. Second, another dynamic reconstruction was performed, incorporating the frame-dependent attenuation map obtained in the first step as well as standard corrections for dead-times, random and scattered coincidences. Note that the attenuation map used during reconstruction also accounted for “static” attenuating medium, such as the scanner’s table and MR head coil. Third, activity volumes in each scanning session were smoothed with a 4-mm FWHM Gaussian filter and rigidly registered to a selected reference frame, followed by another registration to the resulting time-averaged volume. Lastly, all the frames in each session were aligned to a common reference frame, taken as the first session’s time-average image volume. All PET reconstructions were performed using OP-OSEM 3D with 3 iterations and 21 subsets on a 344 × 344 × 127 array with voxel size 2.08 × 2.08 × 2.03 mm³. Image registrations were performed using FSL’s flirt method with normalized mutual information as the data consistency criterion and 6 degrees of freedom. To further mitigate motion effects, realignment transformations estimated during the third step were inspected to discard frames associated with substantial frame-to-frame shifts (> 2.5 mm) from the analysis. Linear interpolation was used to compute time points corresponding to discarded frames as well as missing time points between scanning sessions.

Afterwards, the structural MRI scan for each subject was rigidly aligned to PET space (FSL, flirt), followed by non-rigid registration (FSL, fnirt) of the Montreal Neurological Institute (MNI) template to MRI space for definition of regions of interest (ROIs). In keeping with the range of behavioral symptoms associated with FXS, we explored 18 brain regions that have been implicated across neuroimaging studies of FXS. [18F]FPEB concentration histories were extracted in the following bilateral regions: caudate nucleus, superior temporal gyrus, amygdala, insula, thalamus, primary motor cortex, olfactory cortex, hippocampus, precuneus, prefrontal cortex, parahippocampal gyrus, primary motor cortex, supplementary motor area, superior parietal gyrus, inferior temporal gyrus and cerebellar white matter. Regional time-activity curves (TACs) were fitted using MRTM to estimate [18F]FPEB binding potential (BPND) with the cerebellum white matter as reference. The t* value was fixed at t* = 30 min and the k₂ value was estimated by first-pass MRTM analysis of the average TACs. In addition, for visualization purposes, images of [18F]FPEB BPND were generated for each subject by application of MRTM analysis at the voxel level. BPND images were then transformed to MNI space, followed by spatial Gaussian smoothing (5-mm FWHM) and averaging over subjects in each group.

**Statistical analyses.** Unpaired t-tests (2-tailed) were applied to test the null hypothesis of no difference in [18F]FPEB BPND between healthy controls and subjects with FXS for all surveyed regions. The p-values were corrected for multiple comparisons by applying the Benjamini, Krieger and Yekutieli false discovery rate method with q = 0.05.
Data availability
All datasets generated and/or analyzed during the current study are available from the corresponding authors on reasonable request.

Received: 25 May 2021; Accepted: 16 July 2021
Published online: 05 August 2021

References
1. Verkerk, A. J. et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65, 905–914 (1991).
2. Budimirovic, D. B. & Subramaniam, M. Neurobiology of autism and intellectual disability: Fragile X syndrome. In Neurobiology of Disease 2nd edn (ed. Johnston, M. V.) 375–384 (Oxford University Press, 2016).
3. Hagerman, R. J., Rivera, S. M. & Hagerman, P. J. The fragile x family of disorders; a model for autism and targeted treatments. Curr. Pediatr. Rev. 4, 40–52 (2008).
4. Bear, M. F., Huber, K. M. & Warren, S. T. The mGluR theory of fragile x mental retardation. Trends Neurosci. 27, 370–377 (2004).
5. Burket, J. A. et al. Complex effects of mGluR5 antagonism on sociability and stereotypic behaviors in mice: Possible implications for the pharmacology of autism spectrum disorder. Brain Res. Bull. 86, 152–158 (2011).
6. Thomas, A. M. et al. Group 1 metabotropic glutamate receptor antagonists alter select behaviors in a mouse model of Fragile X syndrome. Psychopharmacology 219, 47–58 (2012).
7. Huber, K. M., Gallagher, S. M., Warren, S. T. & Bear, M. F. Altered synaptic plasticity in a mouse model of Fragile X mental retardation. PNAS USA 99, 7746–7750 (2002).
8. Weiler, I. J. et al. Fragile X Mental Retardation Protein is translated near synapses in response to neurotransmitter activation. PNAS USA 94, 5395–5400 (1997).
9. Budimirovic, D. B. et al. Updated report on tools to measure outcomes of clinical trials in fragile X syndrome. J. Neurodev. Disord. 9, 14 (2017).
10. Duy, P. Q. & Budimirovic, D. B. Fragile X Syndrome: Lessons learned from the most translated neurodevelopmental disorder in clinical trials. Transl. Neurosci. 8, 7–8 (2017).
11. Erickson, C. A. et al. Fragile X targeted pharmacotherapy: Lessons learned and future directions. J. Neurodev. Disord. 9, 7 (2017).
12. Budimirovic, D. B. et al. A genotype-phenotype study of high-resolution FMR1, nucleic acid and protein analyses in Fragile X patients with neurobehavioral assessments. Brain Sci. 10, 694 (2020).
13. Loesch, D. Z., Huggins, R. M. & Hagerman, R. J. Phenotypic variations and FMRP levels in Fragile X, Mental Retard. Dev. Disabil. Res. Rev. 10, 31–41 (2004).
14. Wang, J.-Q., Tueckmantel, W., Zhu, A., Pellegrino, D. & Brownell, A.-L. Synthesis and preliminary biological evaluation of 3-[18F] Fluoro-5-(2-pyridinyl ethyl)benzonitrile ([18FFPEB] as a PET radiotracer for imaging metabotropic glutamate receptor subtype 5. Synapse 61(12), 951–961 (2007).
15. Ichise, M. et al. Linearized reference tissue parametric imaging methods: Application to [11C] DASB positron emission tomography studies of the serotonin transporter in human brain. J. Cereb. Blood Flow Metab. 23(9), 1096–1112 (2003).
16. Sullivan, J. M. et al. Kinetic analysis of the metabotropic glutamate subtype 5 tracer [18F]FPEB in bolus and bolus-plus-constant-infusion studies in humans. J. Cereb. Blood Flow Metab. 33(4), 532–541 (2013).
17. Briačić, J. R. et al. Reduced expression of cerebral metabotropic glutamate receptor subtype 5 in men with Fragile X Syndrome. Brain Sci. 10(12), 899 (2020).
18. Benjamini, Y., Krieger, A. M. & Yekutieli, D. Adaptive linear step-up procedures that control the false discovery rate. Biometrika 93(3), 491–507 (2006).
19. Hall, S. S., Jiang, H., Reiss, A. L. & Greicius, M. D. Identifying large scale brain networks in Fragile X Syndrome. JAMA Psychiat. 70(11), 1215–1223 (2013).
20. Razak, A. K., Dominick, K. C. & Erickson, C. A. Developmental studies in Fragile X Syndrome. J. Neurodev. Disord. 12, 13 (2020).
21. Kwon, H. et al. Functional neuroanatomy of visuospatial working memory in Fragile X Syndrome: Relation to behavior and molecular measures. Am. J. Psychiatry 158(7), 1040–1051 (2001).
22. MacLeod, L. S. et al. A comparative study of the performance of individuals with fragile X syndrome and Fmr1 knockout mice on Hebb-Williams mazes. Genes Brain Behav. 9(1), 53–64 (2009).
23. Bodaleo, F. et al. Structural and functional abnormalities in the olfactory system of Fragile X Syndrome models. Front. Mol. Neurosci. 12, 135 (2019).
24. Arbab, T., Pennartz, C. M. A. & Battaglia, F. P. Impaired hippocampal representation of place in the Fmr1 knockout mouse model of fragile X syndrome. Sci. Rep. 8, 8889 (2018).
25. Kudoh, T. M., Leach, P. T., Silverman, J. L. & Crawley, J. N. Modeling fragile x syndrome in the Fmr1 knockout mouse. Intractable Rare Dis. Res. 3, 118–133 (2014).
26. Spencer, C. M. et al. Altered anxiety-related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome. Genes Brain Behav. 4, 420–430 (2005).
27. Cordeiro, L., Ballinger, E., Hagerman, R. & Hessl, D. Clinical assessment of DSM-IV anxiety disorders in Fragile X Syndrome: Prevalence and characterization. J. Neurodev. Disord. 3, 57–67 (2011).
28. Kaufmann, W. E., Capone, G., Clarke, M. & Budimirovic, D. B. Autism in genetic intellectual disability: Insights into idiopathic autism. In Autism: Current Theories and Evidence (ed. Zimmerman, A. W.) 81–108 (The Humana Press, 2008).
29. Schmitt, L. M., Hessl, D. & Erickson, C. Executive function in Fragile X Syndrome: A systematic review. Brain Sci. 9, 15 (2019).
30. Bruno, J. L. et al. Altered brain network segregation in FXS revealed by structural connectomics. Cereb. Cortex 27, 2249–2259 (2016).
31. Belmonte, M. K. & Bourgeron, T. Fragile X syndrome and autism at the intersection of genetic and neural networks. Nat. Neurosci. 9, 1221–1225 (2006).
32. Berry-Kravis, et al. Drug development for neurodevelopmental disorders: Lessons learned from fragile x syndrome. Nat. Rev. Drug Discov. 17, 280–299 (2018).
33. Protic, D., Salcedo-Arellano, M. J., Dy, J. B., Potter, L. A. & Hagerman, R. J. New targeted treatments for Fragile X Syndrome. Curr. Pediatr. Rev. 15, 251–258 (2019).
34. Berry-Kravis, E., Sumis, A., Hervey, C. & Mathur, S. Clinical-based retrospective analysis of psychopharmacology for behavior in fragile x syndrome. Int. J. Pediatr. 2012(5), 843016 (2012).
35. Lee, A. W., Ventola, P., Budimirovic, D., Berry-Kravis, E. & Visootsak, J. Clinical development of targeted Fragile X treatments: An industry perspective. Brain Sci. 8, 214 (2018).
36. Briačić, J. R., Mathur, A. K. & Budimirovic, D. B. The urgent need for molecular imaging to confirm target engagement for clinical trials of fragile x syndrome and other subtypes of autism spectrum disorder. Arch. Neurosci. 6, e91832 (2019).
37. Brašić, J. R. et al. Cerebral expression of metabotropic glutamate receptor subtype 5 in idiopathic autism spectrum disorder and Fragile X Syndrome: A pilot study. *Int. J. Mol. Sci.* **22**(6), 2863 (2021).
38. Pretto, D. et al. Clinical and molecular implications of mosaicism in FMR1 full mutations. *Front. Genet.* **5**, 318 (2014).
39. Michalon, A. et al. Chronic mGlu5 inhibition corrects fragile X in adult mice. *Neuron* **74**(1), 49–56 (2012).
40. Berry-Kravis, E. et al. A pilot open label single dose trial of fenobam in adults with fragile X syndrome. *J. Med. Genet.* **46**, 266–271 (2009).
41. Dülen, G. et al. Correction of fragile x syndrome in mice. *Neuron* **56**, 955–962 (2014).
42. Lohith, T. G. et al. Is metabotropic glutamate receptor 5 upregulated in prefrontal cortex in fragile x syndrome?. *Mol. Autism* **4**, 15 (2013).
43. Hagerman, R., Au, J. & Hagerman, P. FMR1 premutation and full mutation molecular mechanisms related to autism. *J. Neurodev. Disord.* **3**, 211–224 (2011).
44. Li, Y. et al. MDM2 inhibition rescues neurogenic and cognitive deficits in fragile X mice. *Sci. Transl. Med.* **8**, 336 (2016).
45. Berry-Kravis, E. et al. Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: A randomized, placebo-controlled, phase 2 clinical trial. *Nat. Med.* **27**, 862–870 (2021).
46. Neelamegam, R., Yokell, D., Rice, P., El Fakhri, G. & Brownell, A.-L. Automated radiosynthesis of [18F]FPEB with clinically viable yields for human use. *J. Nucl. Med.* **59**(Suppl 1), 404 (2018).
47. Brownell, A.-L., Zhu, A., Kl, K.-E., Pou taiainen, P. & Choi, J.-K. mGluR5 and not mGluR4 is regionally elevated in fragile X syndrome: Longitudinal PET studies in FXS mouse model. *Mol. Imaging Biol.* **18**, 1554–1859 (2016).
48. Wong, D. F. et al. 18F-FPEB, a PET radio pharmaceutical for quantifying metabotropic glutamate 5 receptors: A first-in-human study of radiochemical safety, biokinetics, and radiation dosimetry. *J. Nucl. Med.* **54**(3), 388–396 (2013).
49. van der Koowe, A. J. W., Benner, T., Salat, D. H. & Fischl, B. Brain morphometry with multiecho MPRAGE. *Neuroimage* **40**(2), 559–569 (2008).
50. Izquierdo-Garcia, D. et al. An SPM-free based approach for attenuation correction combining segmentation and nonrigid template formation: Application to simultaneous PET/MR brain imaging. *J. Nucl. Med.* **55**(11), 1825–1830 (2014).
51. Jenkins, M. & Smith, S. A global optimization method for robust affine registration of brain images. *Med. Image Anal.* **5**(2), 143–156 (2001).
52. Gotthardt, D. et al. Neuroanatomy of fragile X syndrome is associated with aberrant behavior and the fragile X mental retardation protein (FMRP). *Ann. Neurol.* **63**(1), 40–51 (2008).
53. Lightbody, A. A. & Reiss, A. L. Gene, brain, and behavior relationships in Fragile X Syndrome: Evidence from neuroimaging studies. *Dev. Disabil. Res. Rev.* **15**(4), 343–352 (2009).
54. Ichise, M., Toyama, H., Innis, R. B. & Carson, R. E. Strategies to improve neuroreceptor parameter estimation by linear regression analysis. *J. Cereb. Blood Flow Metab.* **22**(10), 1271–1281 (2002).
55. Patel, S. et al. Species differences in mGluR5 binding sites in mammalian central nervous system determined using in vitro binding with [18F]F-PEB. *Nucl. Med. Biol.* **34**(8), 1009–1017 (2007).

Acknowledgements
We would like to thank Grae Arabasz, Regan Butterfield and Shirley Hsu for technical assistance with data collection, and Seppo Ahlfors for advice on subject setup, acclimatization, and training. Our gratitude goes to the participants with FXS and their families for their willingness to take part and help with making this study possible. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs, through the Peer Reviewed Medical Research Program under Award No. W81XWH-17-1-0228 to ALB.

Author contributions
A.L.B. and M.M. conceived and designed this study. P.H., C.M. and M.M. conducted the experiments. D.K. assisted with recruiting and screening subjects; R.N. and D.Y. were responsible for locally synthesizing FPEB; D.Y. supervised the production, scheduling and delivery of the radioligand; Y.P. analyzed the data with guidance from M.N., M.M. and A.L.B. M.M. and Y.B. prepared the manuscript assisted by A.L.B. All authors contributed to critically reviewing this work and approved the final version.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to M.M.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021